L
LTZ Therapeutics
Biotech & Life Sciences · Redwood City, United States · Founded 2021
Develops novel immunotherapies to treat patients that suffer from cancer and other diseases with an unmet clinical need MoreLess
LTZ Therapeutics is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapies for the treatment of cancer and autoimmune diseases. The company's proprietary Myeloid Engager Platform is designed to activate and enhance the function of myeloid cells, a type of immune cell, to generate a robust and durable anti-tumor response.
LTZ's lead product candidate, LTX-001, is a monoclonal antibody that targets a specific receptor on myeloid cells and is currently in Phase 1 clinical trials for the treatment of solid tumors. The company is also developing a pipeline of other myeloid engager candidates for various cancer indications and autoimmune diseases. With operations in both the United States and China, LTZ Therapeutics is strategically positioned to access global talent and resources to advance its innovative pipeline.
Keywords: immunotherapy, oncology, autoimmune diseases, myeloid engager, monoclonal antibody, clinical-stage, biopharmaceutical, cancer treatment, solid tumors, drug development
Company overview
LTZ Therapeutics company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2021
- Headquarters
- Redwood City, United States
- Employees
- 43
- Open positions
- 1
- Dealroom signal
- 86.7
Valuation & funding
LTZ Therapeutics funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VCOther financing | May 2026 | $38M | $400M | GL Ventures | ↗ |
| SERIES AOther financing | Apr 2025 | $40M | $400M | Hillhouse Capital · Zoo Capital · BlueRun Ventures · 5Y Capital | ↗ |
| SERIES AOther financing | Jul 2024 | $20M | $80M | Shunwei Capital · Lapam Capital · GL Ventures · K2 Venture Partners | ↗ |
| SEEDOther financing | May 2023 | $10M | $85M | Shunwei Capital · K2VC · Qiming Venture Partners · Shenzhen Leaguer Venture Capital | ↗ |
| SEEDOther financing | Apr 2022 | $17M | $68M | Qiming Venture Partners · K2 Venture Capital · Hangzhou Tigermed · K2 Global | ↗ |
| LATE VCOther financing | Dec 2021 | Qiming Venture Partners | — |
Growth signals
LTZ Therapeutics website traffic
Latest recorded traffic for LTZ Therapeutics is 2.3K monthly website visits, up 109.1% over the last three months. LTZ Therapeutics's team grew 4.9% over the past year.
Comparisons
LTZ Therapeutics compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
LTZ Therapeutics's talent
Source: Dealroom Talent Intelligence.
Investors
15 investors on LTZ Therapeutics's cap table
Sourced from Dealroom's funding and investor records. Investor profile links are shown where available.
Global footprint
Where LTZ Therapeutics has talent and traffic
team presence
In the news
Latest news about LTZ Therapeutics
Recent press, funding announcements, and product moves mentioning LTZ Therapeutics — open to read from the original sources.
Market sentiment
What the market is saying about LTZ Therapeutics
An AI-synthesized read of the highest-engagement posts about LTZ Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See LTZ Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.